Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...
In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...
Hosted on MSN17d
Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently?In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates ...
$MTSR insiders have traded $MTSR stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates. The bank highlighted Metsera's (NASDAQ:MTSR) long-acting GLP-1RA asset ...
Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback